Literature DB >> 22805106

Validation and interpretation of the Dutch version of the Multiple Sclerosis Neuropsychological Screening Questionnaire.

Judith M Sonder1, Lidwine B Mokkink, Femke A H van der Linden, Chris H Polman, Bernard M J Uitdehaag.   

Abstract

BACKGROUND: The Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ) was developed for screening of MS patients at risk for cognitive impairment with a patient self-report (MSNQ-P) and an informant version (MSNQ-I). The objective of this study was to validate the Dutch versions and determine their interpretability.
METHODS: The MSNQ was completed by 121 MS patients and their partners (informants). We investigated the factor structure, internal consistency and construct validity. Interrater reliability between MNSQ-P and MSNQ-I was investigated with the intraclass correlation coefficient (ICC) and Cohen's kappa. For interpretability of both MSNQ versions we calculated sensitivity, specificity and cut-off scores. Receiver operating characteristic (ROC) curves with related area under the curve (AUC) were used to evaluate the added value of combining both versions.
RESULTS: We found a unidimensional factor structure. Cronbach's alphas were 0.93 and 0.94 for MSNQ-P and MSNQ-I, respectively. The ICC was 0.59 and kappas were ≤0.50. No cut-off score could be defined for the MSNQ-P because of low sensitivity. For the MSNQ-I, sensitivity was 0.75 and specificity 0.71 (AUC 0.80). The cut-off score was 21. ROC curve analyses showed no added value of the MSNQ-P when used in combination with the MSNQ-I.
CONCLUSIONS: The MSNQ-I is preferred over the MSNQ-P to screen MS patients for cognitive impairment.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22805106     DOI: 10.1016/j.jns.2012.06.024

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Factors associated with health-related quality of life among older people with multiple sclerosis.

Authors:  Marijean Buhse; Wendy M Banker; Lynn M Clement
Journal:  Int J MS Care       Date:  2014

2.  The Effects of Cognitive Rehabilitation on Relapsing Remitting Multiple Sclerosis Patients.

Authors:  İlknur Güçlü Altun; Dursun Kirbaş; Deniz Utku Altun; Aysun Soysal; Pakize Nevin Sütlaş; Demet Yandim Kuşçu; Neslihan Behrem Gayir; Ekim Arslan; Barış Topçular
Journal:  Noro Psikiyatr Ars       Date:  2015-06-01       Impact factor: 1.339

3.  Reliability and Validity of a Danish Version of the Multiple Sclerosis Neuropsychological Screening Questionnaire.

Authors:  Tobias Sejbæk; Morten Blaabjerg; Pippi Sprogøe; Mads Ravnborg
Journal:  Int J MS Care       Date:  2018 Jan-Feb

4.  Translation, cross-cultural adaptation and validation of the Portuguese version of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis.

Authors:  Déborah S Sales; Regina Mp Alvarenga; Claudia Cf Vasconcelos; Roberta G Silva; Luiz Cs Thuler
Journal:  Springerplus       Date:  2013-07-22

5.  Cognitive rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial.

Authors:  Ilse M Nauta; Anne E M Speckens; Roy P C Kessels; Jeroen J G Geurts; Vincent de Groot; Bernard M J Uitdehaag; Luciano Fasotti; Brigit A de Jong
Journal:  BMC Neurol       Date:  2017-11-21       Impact factor: 2.474

6.  Estimating Everyday Neuropsychological Functioning in Multiple Sclerosis: Reliability and Validity of the Greek Multiple Sclerosis Neuropsychological Questionnaire.

Authors:  Eleni Konstantinopoulou; Panagiotis Ioannidis; Christos Bakirtzis; Virginia Giantzi; Theodora Afrantou; Dimitrios Parissis; Lambros Messinis; Grigorios Nasios; Nikolaos Grigoriadis
Journal:  Mult Scler Int       Date:  2018-09-25

7.  The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.

Authors:  Ilse M Nauta; Lisanne J Balk; Judith M Sonder; Hanneke E Hulst; Bernard Mj Uitdehaag; Luciano Fasotti; Brigit A de Jong
Journal:  Mult Scler       Date:  2018-05-18       Impact factor: 6.312

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.